Gables Capital Management Inc. Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Gables Capital Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,675 shares of the biopharmaceutical company’s stock after selling 775 shares during the period. Gables Capital Management Inc.’s holdings in Gilead Sciences were worth $339,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the 4th quarter worth about $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC boosted its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 260 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on GILD shares. Morgan Stanley lifted their price objective on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Daiwa America upgraded Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Citigroup started coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Finally, DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.24.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders sold 293,356 shares of company stock valued at $29,166,240. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Down 0.2 %

NASDAQ GILD opened at $117.21 on Tuesday. The stock has a market capitalization of $145.97 billion, a P/E ratio of 316.78, a P/E/G ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a 50-day moving average price of $100.12 and a 200 day moving average price of $91.91. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.70%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.